Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 3/20 | 0.62 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.59 |
| ▸ | PLAT | P00750 | 1/20 | 0.57 |
| ▸ | TCF4 | P15884 | 2/20 | 0.56 |
| ▸ | CTNNB1 | P35222 | 2/20 | 0.56 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.56 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.56 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.56 |
| ▸ | PTPN5 | P54829 | 1/20 | 0.56 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.56 |
| ▸ | IDH1 | O75874 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | SLC40A1 | Q9NP59 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6078558 | 0.94 | TCF4 (0.65) | PLAUPLATTCF4CTNNB1IDH1 | |
| SCHEMBL6078100 | 0.91 | TCF4 (0.68) | PLAUAKR1C3PLATTCF4CTNNB1 | |
| SCHEMBL6079092 | 0.87 | PLAU (0.61) | PLAUAKR1C3PLATTCF4CTNNB1 | |
| SCHEMBL6079117 | 0.86 | AKR1C3 (0.79) | AKR1C3MAPT | |
| SCHEMBL6078109 | 0.86 | PLAU (0.72) | PLAUPLATTDP1MAPT | |
| SCHEMBL6079320 | 0.83 | PLAU (0.73) | PLAUPLATTDP1MAPT | |
| SCHEMBL6429769 | 0.82 | TCF4 (0.53) | PLAUPLATTCF4CTNNB1IDH1 | |
| SCHEMBL6427777 | 0.82 | PLAU (0.66) | PLAUPLATTDP1MAPT | |
| SCHEMBL6078913 | 0.81 | KDM4E (0.67) | PLAUPLATTCF4CTNNB1 | |
| SCHEMBL7313388 | 0.81 | PLAU (0.77) | PLAUAKR1C3PLATTCF4CTNNB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7071231-B2 | Naphthalene ureas as glucose uptake enhancers | TELIK, INC. (US) | 2006-07-04 | — | — | US | disclosed |
| EP-1181271-B1 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2005-01-19 | — | — | EP | disclosed |
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | SPEVAK WAYNE R (US) | 2003-07-17 | — | — | US | disclosed |
| US-6458998-B1 | NAPHTHALENEUREAS AS ANTIDIABETIC AGENTS | TELIK, INC. | 2002-10-01 | — | — | US | disclosed |
| EP-1181271-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | Telik, Inc. (US) | 2002-02-27 | — | — | EP | disclosed |
| WO-2000071506-A9 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK INC (US) | 2001-09-20 | — | — | WO | disclosed |
| WO-2000071506-A2 | NAPHTHALENE UREAS AS GLUCOSE UPTAKE ENHANCERS | TELIK, INC. (US) | 2000-11-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030135063-A1 | Novel naphthalene ureas as glucose uptake enhancers | GPR119, SLC2A8, SLC2A1 | PLAU 1726/4885AKR1C3 1258/4885PLAT 3541/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.